Department and Laboratory of Intensive Care Medicine, KU Leuven, Leuven, Belgium.
Department of Emergency and Intensive Care, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.
Neurocrit Care. 2021 Jun;34(3):722-730. doi: 10.1007/s12028-021-01221-4. Epub 2021 Apr 12.
In patients with aneurysmal subarachnoid hemorrhage (aSAH) the burden of intracranial pressure (ICP) and its contribution to outcomes remains unclear. In this multicenter study, the independent association between intensity and duration, or "dose," of episodes of intracranial hypertension and 12-month neurological outcomes was investigated.
This was a retrospective analysis of multicenter prospectively collected data of 98 adult patients with aSAH amendable to treatment. Patients were admitted to the intensive care unit of two European centers (Medical University of Innsbruck [Austria] and San Gerardo University Hospital of Monza [Italy]) from 2009 to 2013. The dose of intracranial hypertension was visualized. The obtained visualizations allowed us to investigate the association between intensity and duration of episodes of intracranial hypertension and the 12-month neurological outcomes of the patients, assessed with the Glasgow Outcome Score. The independent association between the cumulative dose of intracranial hypertension and outcome for each patient was investigated by using multivariable logistic regression models corrected for age, occurrence of delayed cerebral ischemia, and the Glasgow Coma Scale score at admission.
The combination of duration and intensity defined the tolerance to intracranial hypertension for the two cohorts of patients. A semiexponential transition divided ICP doses that were associated with better outcomes (in blue) with ICP doses associated with worse outcomes (in red). In addition, in both cohorts, an independent association was found between the cumulative time that the patient experienced ICP doses in the red area and long-term neurological outcomes. The ICP pressure-time burden was a stronger predictor of outcomes than the cumulative time spent by the patients with an ICP greater than 20 mmHg.
In two cohorts of patients with aSAH, an association between duration and intensity of episodes of elevated ICP and 12-month neurological outcomes could be demonstrated and was visualized in a color-coded plot.
在颅内动脉瘤性蛛网膜下腔出血(aSAH)患者中,颅内压(ICP)的负担及其对预后的影响尚不清楚。在这项多中心研究中,我们研究了颅内高血压发作的强度和持续时间或“剂量”与 12 个月神经功能预后之间的独立相关性。
这是一项对多中心前瞻性收集的 98 例适合治疗的 aSAH 成年患者数据的回顾性分析。患者于 2009 年至 2013 年期间被收入欧洲两家中心(奥地利因斯布鲁克医科大学和意大利蒙扎圣杰尔达大学医院)的重症监护病房。颅内高血压的剂量通过可视化方法进行评估。通过获得的可视化结果,我们可以研究颅内高血压发作的强度和持续时间与患者 12 个月神经功能预后(使用格拉斯哥结局评分进行评估)之间的关系。使用多变量逻辑回归模型校正患者年龄、迟发性脑缺血的发生以及入院时格拉斯哥昏迷评分,对颅内高血压累积剂量与每个患者预后之间的独立相关性进行研究。
持续时间和强度的组合定义了两个患者队列对颅内高血压的耐受程度。半指数转换将与更好结局相关的 ICP 剂量(蓝色)与与更差结局相关的 ICP 剂量(红色)区分开来。此外,在两个队列中,都发现患者经历 ICP 红色区域剂量的累积时间与长期神经功能预后之间存在独立相关性。与患者 ICP 大于 20mmHg 的时间相比,ICP 压力-时间负担是预后的更强预测因素。
在两个 aSAH 患者队列中,颅内高血压发作的持续时间和强度与 12 个月神经功能预后之间存在相关性,并通过彩色编码图进行可视化。